参考资料: [1]LEXEO TherapeuticsAnnounces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease. Retrieved March 2, 2022, from网页链接 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之...